Methylenetetrahydrofolate reductase gene variants and antipsychotic-induced weight gain and metabolic disturbances.
J Psychiatr Res
; 54: 36-42, 2014 Jul.
Article
en En
| MEDLINE
| ID: mdl-24725652
Weight gain and metabolic disturbances represent serious side-effects in antipsychotic (AP) treatment, particularly with clozapine and olanzapine. The methylenetetrahydrofolate reductase (MTHFR) gene is a key determinant in the folate metabolism and previous studies reported a significant effect on AP-induced weight gain and related metabolic abnormalities. Thus, we investigated MTHFR gene variants and changes in several important metabolic parameters in AP-treated patients. In this study, two functional MTHFR polymorphisms, rs1801133 (C677T) and rs1801131 (A1298C), were investigated for changes in weight and metabolic parameters. Genotypic associations were evaluated in a large population (n = 347 including 66 first episode psychosis, FEP patients) treated mostly with clozapine and olanzapine. We did not detect any genotypic association with weight changes (p > 0.05) in our total sample and in the sample refined for ancestry and medication. In our allelic analyses, we observed a trend for the 677-C allele to be associated with weight gain in the total sample (p = 0.03). This effect appeared to be driven by the FEP patients where those carrying the C-allele gained, on average, twice as much weight. Exploratory analyses revealed a significant association between the C677T and the A1298C polymorphism with HDL cholesterol serum levels in patients (p = 0.031). Overall we did not detect a major effect of two functional MTHFR gene variants and AP-induced weight gain. However, our findings suggest an effect of the C677T polymorphism in FEP patients and changes in weight and cholesterol levels. Further investigations in a larger sample are required.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Antipsicóticos
/
Aumento de Peso
/
Polimorfismo de Nucleótido Simple
/
Metilenotetrahidrofolato Reductasa (NADPH2)
/
Enfermedades Metabólicas
Tipo de estudio:
Prognostic_studies
Idioma:
En
Revista:
J Psychiatr Res
Año:
2014
Tipo del documento:
Article